Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
NCT ID: NCT05815160
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
34 participants
INTERVENTIONAL
2023-05-02
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the recommended dose when administered in combination with carboplatin and etoposide.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin
Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
Debio 0123
Administered as capsules.
Etoposide
Administered as IV infusion.
Carboplatin
Administered as IV infusion.
Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin
Participants will receive Debio 0123 recommended dose determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
Debio 0123
Administered as capsules.
Etoposide
Administered as IV infusion.
Carboplatin
Administered as IV infusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Debio 0123
Administered as capsules.
Etoposide
Administered as IV infusion.
Carboplatin
Administered as IV infusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Tumor that is not bleeding
3. Prior platinum-based chemotherapy (carboplatin and/or cisplatin)
* Part 1 (dose escalation): Recurrence or progression after a minimum of 45 days since the last dose of prior standard platinum-based therapy
* Part 2 (expansion): Recurrence or progression after a minimum of 90 days since the last dose of prior standard platinum-based therapy
4. Measurable disease per RECIST 1.1
5. Willingness and ability to undergo tumor biopsy unless an archived tumor sample is available
6. ECOG performance status of 0-1
7. Life expectancy of at least 3 months in the best judgment of the Investigator
8. Adequate bone marrow, hepatic and renal function, adequate coagulation status
9. Willingness and ability to comply with scheduled visits, study treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria
2. History of other malignancies requiring active treatment in the last 2 years prior to first dose of study treatment, except for superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated with curative intent.
3. History of myocardial infarction or stroke in the last 6 months prior to first dose of study treatment, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, known family history of sudden death from cardiac-related causes before the age of 50, or any cardiotoxicity experienced after previous chemotherapy.
4. Left ventricular ejection fraction (LVEF) below 55%.
5. QTcF \>450 ms, history of congenital long QT syndrome, or clinically significant conduction abnormality, or any conduction abnormality that may increase the risk of TdP.
6. Clinically significant gastrointestinal abnormality that could affect the absorption of orally administered drugs
7. Major surgery ≤4 weeks prior to first dose of study treatment or incomplete recovery from the surgical procedure at the time of the first dose of study treatment.
8. Radiographic findings showing tumor involvement with large blood vessels or poor demarcation from them with increased risk for bleeding.
9. Radiographic findings of Interstitial lung disease (ILD) that are considered clinically significant.
10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
11. Any infection requiring the systemic use of an antibiotic or antiviral agent.
12. Known Hepatitis C virus (HCV), Hepatitis B virus (HBV), or Human Immunodeficiency Virus (HIV) infection. Participants with past infections that have been cured may be enrolled.
13. Immunization with live or live-attenuated vaccine within 28 days prior to first dose of study treatment.
14. Inability or unwillingness to swallow oral medications.
15. Anticancer treatment (including chemotherapy), monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to first dose of study treatment. Palliative radiation is allowed up to 1 week prior to study treatment start.
16. Unresolved AEs or toxicities due to previous treatments \>Grade 1. Note: Participants with ≤Grade 2 alopecia or endocrinopathies controlled by replacement therapy are exceptions and may qualify for the study.
17. Hypersensitivity to Debio 0123, etoposide or carboplatin, or any of the excipients found in the formulations for Debio 0123, etoposide, or carboplatin. If a prior hypersensitivity to carboplatin has been observed but a successful desensitization was performed for the participant, he or she may be eligible for the study.
18. Prior exposure to any WEE1 inhibitor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Debiopharm International SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Hospital Universitario de A Coruna
A Coruña, , Spain
Hospital Universitario Vall d'Hebron
Barcelona, , Spain
Hospital Clinic Barcelona
Barcelona, , Spain
Institut Catala D'Oncologia - Badalona
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
Clinica Universidad de Navarra
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC)
Madrid, , Spain
NEXT Oncology Madrid
Madrid, , Spain
Hospital Quironsalud Malaga
Málaga, , Spain
Clinica Universidad de Navarra
Pamplona, , Spain
Hospital Clinico Universitario de Valencia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-510980-40-00
Identifier Type: CTIS
Identifier Source: secondary_id
U1111-1302-8787
Identifier Type: OTHER
Identifier Source: secondary_id
Debio 0123-SCLC-104
Identifier Type: -
Identifier Source: org_study_id